ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sino Biopharmaceutical's annualizedNet Income for the quarter that ended in Dec. 2025 was $-297 Mil.
Sino Biopharmaceutical's average Total Assets over the quarter that ended in Dec. 2025 was $10,611 Mil. Therefore, Sino Biopharmaceutical's annualized ROA % for the quarter that ended in Dec. 2025 was -2.80%.
The historical rank and industry rank for Sino Biopharmaceutical's ROA % or its related term are showing as below:
SBMFF'
s ROA % Range Over the Past 10 Years
Min: 3.25 Med: 7.47 Max: 35.57
Current: 3.25
During the past 13 years, Sino Biopharmaceutical's highest ROA % was 35.57%. The lowest was 3.25%. And the median was 7.47%.
SBMFF's ROA % is ranked better than 85.16% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs SBMFF: 3.25
Sino Biopharmaceutical (OTCPK:SBMFF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sino Biopharmaceutical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's ROA % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sino Biopharmaceutical (SBMFF) has a ROA % of -2.80% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sino Biopharmaceutical and its competitors. Over the past decade, Sino Biopharmaceutical's ROA % has ranged from 3.25 to 35.57. According to the industry distribution chart, Sino Biopharmaceutical ranks #211 out of 1422 companies in the Biotechnology industry, placing it in the top 14.8%.
Is Sino Biopharmaceutical's ROA % too high?
Sino Biopharmaceutical's current ROA % is -2.80%. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 35.57. Based on the distribution chart, Sino Biopharmaceutical ranks #211 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #211 out of 1422 companies for ROA %. This places Sino Biopharmaceutical in the top 15% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own ROA % has ranged from 3.25 to 35.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current ROA % is -2.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.66, compared to a current price of $0.60 — trading 8.8% below its estimated fair value. The current ROA % is -2.80%. Sino Biopharmaceutical's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current ROA % is -2.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 8.8% below its estimated GF Value™ of $0.66.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
ROA %: -2.80%
GF Value™: $0.66 vs. price of $0.60 (8.8% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
63GF Score
Get the complete analysis for SBMFF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
